London, May 14, 2026, 14:05 BST
Tate & Lyle PLC confirmed Thursday it’s in discussions with Ingredion, its U.S. rival, regarding a potential all-cash takeover that puts Tate & Lyle’s value near £2.74 billion, or $3.70 billion. The latest approach would pay shareholders up to 615 pence per share—595 pence in cash, plus a possible 20 pence in dividends.
Tate & Lyle is suddenly in play just a week out from its full-year numbers, handing investors a potential way out after tough times for both demand and margins. The bid also presses buyers on what premium they’re prepared to put on London-listed speciality ingredients firms, especially as these groups look to pivot from slower-moving commodity segments.
Shares surged 52% to 569.50 pence in early afternoon trading in Europe, but that’s short of the takeover offer. The spread is telling—the market isn’t pricing this as a sure thing.
Tate & Lyle releases its FY2026 numbers May 21, when Chief Executive Nick Hampton and CFO Sarah Kuijlaars will face analysts in London. The timing of the approach isn’t ideal, but it’s no surprise—investors had been pressing for more clarity on how the CP Kelco deal fits in and what management sees for growth ahead.
Back in February, Hampton called top-line growth the company’s “number one priority.” In the same update, pro forma revenue for the nine months through Dec. 31 dropped 3% at constant currency. Tate & Lyle still expects both 2026 revenue and EBITDA to slip by a low-single-digit percentage. EBITDA, or earnings before interest, tax, depreciation and amortisation, is the standard gauge for operating profit before those costs.
Still, there’s no binding offer on the table. Tate & Lyle made it clear—no guarantee Ingredion will move forward, or that any bid terms are set. The company put out the statement without Ingredion’s approval, and that possible dividend? It hinges on getting the usual thumbs up from the board and shareholders.
The Takeover Panel’s disclosure table puts Tate & Lyle’s offer period as starting at 13:07 BST on Thursday, with a 17:00 BST deadline on June 11 for Ingredion to either confirm a firm bid or walk away. The clock’s meant to push for a decision, but the Panel can extend it if needed.
Ingredion isn’t a private equity player—it’s buying straight from within the industry. The Chicago-area firm logged roughly $7.2 billion in net sales for 2025, supplying ingredients from grains, fruits, vegetables, and other plant sources to customers in over 120 countries.
Ingredion would pick up extra heft in sweeteners, fibre, starches, and mouthfeel ingredients—those additives that tweak texture in foods and drinks—by bringing Tate & Lyle into the fold. Shareholders at Tate & Lyle, on the other hand, would get value locked in ahead of any real market verdict on whether the CP Kelco tie-up pays off.
Tate & Lyle wrapped up its CP Kelco purchase from J.M. Huber in November 2024, expanding its lineup with pectin, speciality gums, and other natural ingredients. Huber picked up about a 16% stake via consideration shares—significant, with a formal offer likely to draw extra attention from shareholders.
The real issue now: will Ingredion move from a conditional stance to a firm bid? Until that’s settled, Tate & Lyle shares probably won’t behave like your typical food ingredients name. Instead, the stock is likely to trade as a deal spread, with every fresh development judged against that 615p figure.
